Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study.

Tobias Moser* (First author), Ciara OSullivan, Ferdinand Otto (Co-author), Wolfgang Hitzl (Co-author), Georg Pilz (Co-author), Kerstin Schwenker (Co-author), Cornelia Mrazek (Co-author), Elisabeth Haschke-Becher (Co-author), Eugen Trinka (Co-author), Peter Wipfler (Co-author), Andrea Harrer* (Last author)

*Corresponding author for this work

Research output: Contribution to journalOriginal Article (Journal)peer-review

6 Citations (Web of Science)
Original languageEnglish
Pages (from-to)17562864221092092
JournalTHERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
Volume15
DOIs
Publication statusPublished - 2022

Keywords

  • OCRELIZUMAB
  • PLACEBO

Cite this